Atopic Dermatitis Research Study
The main purpose of this study is to test if the study drug, tralokinumab, is better than a placebo at treating moderate to severe atopic dermatitis (a type of eczema) in adolescents between the ages of 12 to 17 years.
The study will last up to 72 weeks, and there will be up to 30 visits at the clinic and 2 telephone contacts by the study staff. The visits at the clinic will typically be every second week. There will be a possibility for transfer to known treatment of tralokinumab after 16 weeks if no response to study treatment in the previous 16 weeks.
If interested in participating in this clinical study, call: 502.368.0732
Request More Information About This Study